Endothelin-1 gene polymorphism (G8002A) and endothelial monocyte-activating polypeptide II: Role in vascular dysfunction in pediatric patients with β-thalassemia major

• Published in: Cytokine (Philadelphia, Pa.) Pa.), 2023-01, Vol.161, p.156048-156048, Article 156048
• Main Authors: Tantawy, Azza Abdel Gawad, Tadros, Mourad Alfy Ramzy, Adly, Amira Abdel Moneam, Ismail, Eman Abdel Rahman, Ibrahim, Fatma A., Salah Eldin, Nanis Mohammed, Hussein, Mahitab Morsy, Alfeky, Mervat Abdalhameed, Ibrahim, Sarah Mohammed, Hashem, Marwa Adel, Ebeid, Fatma Soliman Elsayed
• Format: Article
• Language: English
• Subjects: beta-Thalassemia - complications; beta-Thalassemia - genetics; beta-Thalassemia - therapy; Child; Endothelin-1 - genetics; Ferritins; Genetic Markers; Heart Diseases - complications; Humans; Kidney Diseases; Polymorphism, Genetic; RNA-Binding Proteins - genetics; Superoxide Dismutase
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2022.156048

Background: Endothelin-1 (ET-1), a potent endogenous vasoconstrictor, stimulates production of reactive oxygen species. Endothelial monocyte-activating polypeptide-II (EMAP-II) is a multifunctional polypeptide. Aim: To assess ET-1 gene polymorphism (G8002A) in pediatric patients with β-thalassemia major (β-TM) as a potential genetic marker for vascular dysfunction and its possible relation to EMAP II, oxidative stress and vascular complications. Methods: β-TM patients (n = 95) without symptomatic cardiac or renal disease were compared with 95 healthy controls. Markers of hemolysis, serum ferritin, urinary albumin-to-creatinine ratio, serum EMAP II, malondialdehyde (MDA) and antioxidant enzymes; superoxide dismutase (SOD), glutathione peroxidase (GPx), reduced glutathione (GSH), glutathione reductase and catalase were measured. ET-1 gene polymorphism (G8002A) was determined using polymerase chain reaction‑restriction fragment length polymorphism. Results: β-TM patients had significantly higher EMAP II than healthy controls. EMAP II was significantly higher among patients with cardiac disease, pulmonary hypertension (PH) risk, nephropathy, poor compliance to therapy and ferritin ≥ 2500 μg/L. There were significant correlations between EMAP II and transfusion index, LDH, ferritin and oxidative stress markers. The AA genotype of ET-1 gene polymorphism (G8002A) was significantly higher among β-TM patients than controls. The number of patients with cardiac disease, PH risk or nephropathy was significantly higher among AA genotype compared with GG and GA genotypes. Lactate dehydrogenase (LDH), serum ferritin, EMAP II, MDA, SOD and GPx were significantly higher in AA genotype. Conclusion:ET-1 gene polymorphism (G8002A) could be a possible genetic marker for prediction of increased susceptibility to cardiopulmonary and renal complications among pediatric patients with β-TM.